RheumaGen, Inc. and SiVEC Biotechnologies, Inc. have entered into a licensing and joint development agreement aimed at revolutionizing the treatment of autoimmune diseases through a novel class of gene-editing therapies. This strategic partnership will leverage SiVEC’s BactPac drug delivery platform to enhance the manufacturing process and scalability of RheumaGen’s human leukocyte antigen (HLA) gene-editing therapies, while also establishing a co-developed in vivo program.
The collaboration comes at a critical time as the cell and gene therapy (CGT) sector grapples with significant challenges, including high costs and complex commercialization pathways. By combining their innovative approaches, both companies aim to deliver cost-effective and accessible therapies to millions of patients suffering from autoimmune conditions. This partnership not only exemplifies the potential of Colorado’s biotech landscape but also highlights a concerted effort to address pressing healthcare needs.
RheumaGen’s lead candidate, RG0401, targets a subset of rheumatoid arthritis patients who are refractory to existing treatments, with plans to initiate Phase I clinical trials by 2027. The therapy aims to selectively edit HLA genes to mitigate autoimmune responses without broadly suppressing the immune system, potentially halting disease progression. As the CGT industry evolves, partnerships like this one may pave the way for more effective and accessible treatments, underscoring the importance of innovation in addressing unmet medical needs.
Get started today with Solo access →
